Page 2 - Alan Stitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alan stitt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alan Stitt Today - Breaking & Trending Today

Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD

Oxurion NV - Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
& Corporate Communications
[email protected] (mailto:[email protected])
EU
Tel: +44 20 7638 9571
[email protected] (mailto:[email protected])
US
[email protected] (mailto:[email protected])
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (AMD) and retinal vein occlusion (RVO). ....

United States , Region Flamande , Wouter Piepers , Sylvie Berrebi Frazer Hall , Christopher Brinzey , Citigate Dewe Rogerson , Progress In Retinal Eye Research , Bicycle Therapeutics , Corporate Communications , Euronext Brussels , Van Hove , Retinal Eye , Alan Stitt , Chief Scientific Officer , ஒன்றுபட்டது மாநிலங்களில் , ப்ரோக்ரெஸ் இல் விழித்திரை கண் ஆராய்ச்சி , மிதிவண்டி சிகிச்சை , பெருநிறுவன தகவல்தொடர்புகள் , வேன் ஹோவ் , விழித்திரை கண் , ஆலன் ஸ்டிட் , தலைமை அறிவியல் அதிகாரி ,

Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of .
Oxurion NVApril 7, 2021 GMT
Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year
Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and rationale for the design and development of THR-687. The article entitled: ....

United States , Region Flamande , Wouter Piepers , Sylvie Berrebi Frazer Hall , Christopher Brinzey , Citigate Dewe Rogerson , Progress In Retinal Eye Research , Bicycle Therapeutics , Corporate Communications , Euronext Brussels , Van Hove , Retinal Eye , Alan Stitt , Chief Scientific Officer , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , ப்ரோக்ரெஸ் இல் விழித்திரை கண் ஆராய்ச்சி , மிதிவண்டி சிகிச்சை , பெருநிறுவன தகவல்தொடர்புகள் , வேன் ஹோவ் , விழித்திரை கண் , ஆலன் ஸ்டிட் , தலைமை அறிவியல் அதிகாரி , முதலீட்டாளர் உறவுகள் ,

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD

Oxurion NV
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD
Oxurion is a leader in the development of pan-RGD integrin antagonists for retinal vascular disorders - THR-687 on track to enter Phase 2 development by mid-year
Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular disorders, announces the publication of a review article describing the cutting-edge science and rationale for the design and development of THR-687. The article entitled: ....

United States , Region Flamande , Wouter Piepers , Sylvie Berrebi Frazer Hall , Christopher Brinzey , Citigate Dewe Rogerson , Progress In Retinal Eye Research , Bicycle Therapeutics , Corporate Communications , Retinal Eye Research , Euronext Brussels , Van Hove , Retinal Eye , Alan Stitt , Chief Scientific Officer , ஒன்றுபட்டது மாநிலங்களில் , ப்ரோக்ரெஸ் இல் விழித்திரை கண் ஆராய்ச்சி , மிதிவண்டி சிகிச்சை , பெருநிறுவன தகவல்தொடர்புகள் , விழித்திரை கண் ஆராய்ச்சி , வேன் ஹோவ் , விழித்திரை கண் , ஆலன் ஸ்டிட் , தலைமை அறிவியல் அதிகாரி ,

Oxurion NV Business and Financial Update

Oxurion NV Business and Financial Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,

Investegate |Oxurion NV Announcements | Oxurion NV: Oxurion NV Business and Financial Update – FY 2020

First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year

THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020

The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.

At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position. ....

United States , Bruxelles Capitale , New York , France General , Region Flamande , Tom Graney , City Of , United Kingdom , Jean Feyen , Ramin Tadayoni , Grace Chang , Dominique Vanfleteren , Arshad Khanani , Sylvie Berrebi Frazer Hall , Los Angeles , Wouter Piepers , Jo Van Ginderachter , Claude Sander , Kathleen Paisley , Citigate Dewe Rogerson , Christopher Brinzey , Yale Law School , Ironwood Pharmaceuticals , Bascom Palmer Eye Institute Angiogenesis , Queen Mary University Of London , University Of Nevada ,